Sonus says data indicates SN2310 improves on irinotecan against cancer

New York, Nov. 15 - Sonus Pharmaceuticals, Inc. said pre-clinical data indicates its SN2310 emulsion shows better anti-tumor activity than irinotecan.

The data also suggested that the formulation of SN2310 may allow less frequent dosing than irinotecan while maintaining the therapeutic effect.

"We are pleased that the development of SN2310 emulsion is continuing to show promise," said Michael Martino, president and chief executive officer of Sonus Pharmaceuticals, in a news release.

"Based on the ongoing strength of the preclinical data, our goal is to work with the FDA [Food and Drug Administration] to move the SN2310 formulation into the first human studies in 2006."

SN2310 is based on camptothecin. Two products containing camptothecin derivatives, topotecan and irinotecan, are currently commericially available for the treatment of colorectal, lung and ovarian cancers. Due to the limited circulating half-life of these derivatives, it is believed that an alternative camptothecin-based product that offers sustained exposure in the body may be optimal for enhancing anti-tumor activity.

The data was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.

Sonus is a Bothell, Wash., company developing drugs for oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.